Funding opportunities
Open and upcoming programs from Canadian funders and US federal grants (Grants.gov). Deadlines first, then rolling intakes.
NIDA Avenir Program: Fundamental Mechanistic Research in Addiction Science
National Institutes of Health · Deadline not published
Avenir, the French word for "future," reflects NIDA's commitment to developing the next generation of leaders in addiction science. Since 2015, the Avenir Program has supported exceptionally creative early stage investigators (ESIs) in launching innovative research programs. NIDA is now expanding this program to support bold mechanistic research across a broader range of addiction science, including genetic, epigenetic, molecular, cellular, circuit, chemical, pharmacological, behavioral, and cognitive processes relevant to Substance Use Disorders (SUDs). This initiative is intended to catalyze high-risk, high-reward research and attract outstanding new investigators, including those from outside the addiction field. Applications proposing novel, unconventional, or interdisciplinary wet-lab and/or data science approaches to advance understanding of the mechanisms underlying SUDs are encouraged. The Avenir Program is designed for ESIs who may lack the preliminary data needed for an R01 application but propose high-impact research and show strong potential to become future leaders in fundamental mechanistic addiction science. Grant authorities that allow NIDA to forecast this opportun Awards up to $375,000.
Implementation and Evaluation of Databases to Examine AIDS
National Institutes of Health · Deadline not published
The National Institute of Allergy and Infectious Diseases (NIAID), with partnering National Institutes of Health Institutes, Centers, and Offices, seeks to advance its mission through continued support for the Implementation and Evaluation of Databases to Examine AIDS Consortium. This research network integrates clinical, epidemiologic, genomic, and contextual real-world data through harmonized data standards and interoperable data systems to generate evidence, perform data-driven research, and advance implementation science. Regional Cohort Centers collaborate across scientific working groups to investigate research priorities and develop innovative analytic methods. The consortium will apply cutting-edge data science approaches and incorporate emerging artificial intelligence technologies through scalable tools, computational models, and workflows to support data sharing, re-use, and reproducibility. The consortium supports studies of HIV morbidity, mortality, comorbidities, and multidimensional risk factors for HIV. As a platform for implementation science, the consortium evaluates strategies to improve HIV prevention, treatment, and care, contributing to the goals of the U.S. E
Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness (ALACRITY) Research Centers
National Institutes of Health · Deadline not published
The National Institute of Mental Health (NIMH) intends to publish a notice of funding opportunity (NOFO) to solicit research applications for practice-based research centers to support interdisciplinary teams of mental health researchers to engage in high-impact studies that will significantly advance clinical practice and generate knowledge to fuel the transformation of mental health care in the United States. Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness (ALACRITY) Research Centers support research projects aimed at the rapid development, testing, and refinement of novel and integrative approaches for (1) optimizing the effectiveness of therapeutic or preventive interventions for mental disorders; (2) developing and testing empirically informed patient-, provider- and system-level interventions to improve mental health care access, engagement, continuity, efficiency, and quality; and (3) continuously improving the quality, impact, and durability of optimized interventions and health for individuals with or at risk for mental health problems, including those with serious mental illness. Notice is being provided t
Limited Competition: NCATS Clinical and Translational Science Award (CTSA) Program Research Education Grants Programs (R25 - Clinical Trial Not Allowed)
National Institutes of Health · Deadline 2027-05-28
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs.
Centers for Structural Biology of HIV and Other Infectious Diseases (U54 Clinical Trial Not Allowed)
National Institutes of Health · Deadline 2027-05-28
The purpose of this notice of funding opportunity (NOFO) is to support multidisciplinary consortia of structural biologists, microbiologists, and associated experts to solve complex biological structures related to the prevention, treatment, and cure of HIV and other infectious diseases. Centers are expected to facilitate new collaborations, leverage shared resources, offer services and resources to the research community, and train the next generation of scientists engaged in structural biology of infectious diseases. Awards up to $3,500,000.
Improved Drug Susceptibility Testing (DST) for Mycobacteria
National Institutes of Health · Deadline not published
The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission by supporting research to develop improved drug susceptibility tests (DSTs) for mycobacterial drugs, including those currently used for treatment of tuberculosis (TB) and clinically important non-tuberculous mycobacterial (NTM) infections, new drugs and drugs in late-stage clinical development. TB is a leading cause of death from an infectious disease worldwide and drug-resistant strains of TB, including those resistant to new drug regimens, are increasing. In the United States, rates of NTM lung disease are rising, especially among women and older adults, while TB cases have surged to their highest level in ten years. Current assays utilize slow, culture-based processes that do not allow for the rapid testing of mycobacterial strains and their drug susceptibility. Improved DSTs are essential for guiding effective treatment, reducing drug-resistant mycobacterial rates, and preventing new transmissions. This program will support the development of innovative DST assays, including rapid genotypic and improved phenotypic methods that do not require full culture growth. Grant authorities that
Childhood Asthma in Urban Settings Clinical Research Network
National Institutes of Health · Deadline not published
The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission through the continued support of the Childhood Asthma in Urban Settings Clinical Research Network (CAUSE) network. The CAUSE network will support multi-site clinical studies and trials on the prevention and treatment of asthma in economically disadvantaged pediatric populations where disease burden is high. The objectives of the CAUSE network are to develop and test innovative hypotheses and strategies for asthma prevention; identify/test new treatment targets (including targets for intervention based on mechanisms of type 2 low asthma); and continue to explore the risk relationship between upper and lower airway. Using systems biology approaches, CAUSE will continue to identify disease endotypes that may be suitable targets for existing and novel therapeutic modalities. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.
Holistic and Evidence-Informed Wellness for STI Prevention
Centers for Disease Control - NCHHSTP · Deadline not published
STIs represent a serious public health and economic burden in the United States (U.S.), with approximately 2.2 million new infections occurring each year. As the nation's lead public health agency, the Centers for Disease Control and Prevention (CDC) has a unique responsibility to provide national leadership in STI prevention and control. To meet this challenge, CDC supports a comprehensive and integrated approach to STI prevention that goes beyond simply addressing the absence of disease. It empowers individuals to make healthy choices and build healthy relationships, as an approach to reducing STIs in the U.S. This whole-person approach focuses not just on physical health, but also considers the emotional, mental, and social well-being of the individual. A key component of this approach is supporting a national coalition of sexual health and wellness expertise that allows for the strategic use of limited resources for STI prevention. The coalition brings together a range of organizations, clinical experts, and individuals committed to comprehensive and holistic sexual health and wellness frameworks for STI prevention. The goal is for them to work together to share clear, accurate
U.S.-Africa Strategic Investment Program
Bureau of African Affairs · Deadline 2027-05-31
The U.S.-Africa Strategic Investment Program advances America's national interests by harnessing market-based, private sector-led growth across two strategic focus areas: Critical Minerals Investment and Commercial Diplomacy Acceleration. This program seeks market-based solutions that strengthen the environment for foreign investment in sub-Saharan Africa through transparent and competitive processes, creating sustainable economic growth in two strategic focus areas. Projects must demonstrate clear, measurable benefits to one or more sub-Saharan countries, such as increased investment from high-quality U.S. and U.S.-aligned companies. Applicants are also encouraged to identify how their projects create conditions that enable U.S. commercial participation. Awards range from $5,000,000 to $50,000,000.
Lifespan Respite Care Program: State Grants
Administration for Community Living · Deadline not published
ACL is seeking applications from eligible state agencies to advance the provision of respite services through statewide Lifespan Respite Care systems, as authorized under the Lifespan Respite Care Act. The program aims to develop or expand state systems and capacity to provide respite care and related services to family caregivers of children and adults across the lifespan, regardless of disability or chronic condition. There are two application options contained in this single NOFO. State Applicants for Option A (Grants to New States and States Re-Establishing Their Core Respite Infrastructures): This opportunity is for states who have never had a Grant before, OR who had a grant before, but the program has stopped, and they wish to start it up again. Intended for states that have never received a grant or those whose programs may have lapsed, and the state wishes to re-establish program activities. State Applicants for Option B (State Program Enhancement Grants): This opportunity is intended for states that have had at least one grant in the past and/or wish to continue building and expanding upon their programmatic activities to enhance and expand the availability of lifespan re Awards range from $300,000 to $500,000.
EPSCoR Graduate Fellowship Program (EGFP)
U.S. National Science Foundation · Deadline 2027-06-01
The NSF EPSCoR Graduate Fellowship Program (EGFP) provides an opportunity for applicants who received the distinction of GRFP Honorable Mention no more than three years before the proposal due date to be named NSF EPSCoR Graduate Fellows and obtain financial support for their graduate education at an institution in an EPSCoR jurisdiction. EGFP aims to enhance the capacity and competitiveness of EPSCoR jurisdictions by providing funding to graduate degree-awarding institutions to support NSF EPSCoR Graduate Fellows as they pursue graduate degrees in the disciplines specified by the NSF Directorates and Office that are participating in the EGFP funding program. Fellows may pursue degrees in field that differ from the field or sub-field of study that the GRFP Honorable Mention recipients previously listed in their GRFP application. EGFP awards will be made to institutions in EPSCoR jurisdictions. Awards will provide three years of stipend and associated cost-of-education allowance for each NSF EPSCoR Graduate Fellow. Stipends must be budgeted at the level of $37,000 per year per Fellow and cost-of-education allowances must be budgeted at the level of $16,000 per year per Fellow. A tot Awards range from $477,000 to $3,180,000.
Antarctic Research Requiring U.S. Antarctic Program (USAP) Support for Fieldwork
U.S. National Science Foundation · Deadline 2027-06-01
Through this solicitation, the Antarctic Sciences Section (ANT) of the Office of Polar Programs (OPP) funds cutting-edge research that requires logistical support from the U.S. Antarctic Program (USAP) and: Improves understanding of interactions among the Antarctic region and global systems. Improves understanding of the dynamic linkages among processes operating in the Antarctic and Southern Ocean and linkages to global Earth systems, which helps inform decision making regarding environmental change. Advances fundamental understanding of Earth systems and the biological, geochemical, and physical processes in the Antarctic and Southern Ocean as drivers and responders to changes on a global scale. Expands fundamental knowledge of Antarctic systems, biota, and processes. Utilizes the unique characteristics of the Antarctic region as a science observing platform. Builds capacity and enhances the US workforce for polar-related science. Antarctic fieldwork is supported only for research that must be performed, or is best performed, in Antarctica. Proposers that do NOT require USAP logistical support should consult the Antarctic Sciences web page for current opportunities. NSF is curren
BRAIN Initiative: Data Archives for the BRAIN Initiative
National Institutes of Health · Deadline not published
The National Institute of Mental Health (NIMH), with other NIH Institutes and Centers (ICs), intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications to develop web-accessible data archives to capture, store, and curate data related to the Brain Research Through Advancing Innovative Neurotechnologies® (BRAIN) Initiative activities. The data archives teams will work with the research community to incorporate software tools that enable users to analyze and visualize the data, and to use appropriate standards to describe the data. A goal of this program is to advance research by creating a data archive that meets appropriate standards and provides summary information which is broadly available and accessible to the scientific community furthering research. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO will utilize the R24 activity code. Applications to this NOFO must propose the development of archives that support rigorous data sharing, analysis, and collaboration across sub-domains while enabling future linkage i
Clinical Data, Safety and Statistical Centers (CDSSC)
National Institutes of Health · Deadline not published
The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission through the support of the Clinical Data, Safety and Statistical Centers program. The overall objective of this program is to provide coordination and oversight for multiple activities in service to clinical research and mechanistic studies supported by NIAID, including all Division of Allergy, Immunology, and Transplantation’s Clinical Network activities. This program will provide a broad range of support critical for the design, development, implementation, and analysis of clinical research carried out by multiple division-supported programs in three disease areas: asthma and allergy, autoimmune diseases and transplantation. Support will include statistical design and analysis, protocol development, study initiation and management, data management, safety monitoring, sample tracking, final analysis of study findings, and manuscript development. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.
NIDDK Disease Research and Translational Core Centers (P30 Clinical Trial Optional)
National Institutes of Health · Deadline not published
This Notice of Funding Opportunity (NOFO) invites applications for NIDDK Disease Research and Translational Core Centers (P30 Clinical Trial Optional ) . These Core Centers are part of an integrated program of biomedical and translational research supporting our cystic fibrosis, diabetes, nutrition, obesity, liver and digestive diseases research. They enhance multidisciplinary collaboration, rigor, reproducibility, replication and research cost efficiencies at institutions that already have a large established research base in one of the above focused areas within NIDDK’s mission. They should also provide a rich mentoring environment for trainees and early-stage investigators. The P30 Centers accomplish their purpose by providing a Pilot and Feasibility Grant Program, a Scientific Catalyst Program, and importantly shared access to the services of Cores. Within a given P30 Center, the Scientific Catalyst Program, which works within the Administrative Core, supports activities that strengthen the Center’s scientific community and advance its research mission. Activities may include research team building, investigator mentoring, seminars, workshops, visiting scientists, and scientifi
National Viral Hepatitis Education, Awareness, and Capacity Building for Communities and Providers
Centers for Disease Control - NCHHSTP · Deadline not published
In alignment with CDC's viral hepatitis strategic goals and current epidemiology, this Notice of Funding Opportunity (NOFO) will address the need for increasing awareness of viral hepatitis prevention, testing, and treatment options among populations disproportionately affected by hepatitis B and/or hepatitis C virus infections. The priority populations' needs will also be addressed by increasing healthcare professionals' competence in the evaluation and treatment of hepatitis B and/or hepatitis C virus infection. The outcomes of this NOFO will be achieved through two separate components. An organization may apply for one component or both components by submitting two separate applications, one for Part A and one for Part B. Part A: Community Education, Awareness, and Capacity Building, and Part B: Professional Education and Training. Strategies and activities conducted under each part may contribute to more people with hepatitis B and hepatitis C able to make informed health decisions and obtain proper care and treatment which can lead to decreased morbidity and mortality from hepatitis B and hepatitis C. Part A strategies and activities focus on 1) leading, maintaining, and growi
Single Source: Scalable and Systematic Neurobiology of Psychiatric and Neurodevelopmental Disorder Risk Genes: Data Resource and Administrative Coordination Center (U24 Clinical Trial Not Allowed)
National Institutes of Health · Deadline not published
The National Institute of Mental Health (NIMH) intends to issue a single-source cooperative agreement award to the University of California, Santa Cruz. The award will renew the Data Resource and Administrative Coordination Center (DRACC), a component of the Scalable and Systematic Neurobiology of Psychiatric and Neurodevelopmental Disorder Risk Genes (SSPsyGene) Consortium. The long-term goal of SSPsyGene is to systematically study how risk genes for neurodevelopmental and psychiatric disorders (NPDs) affect molecular, cellular, circuit, systems/organismal biology. The renewed DRACC will refine its focus on developing a sustainable knowledge base, with shared terms, definitions, and data standards that are interoperable with other knowledge platforms and will enable the use of artificial intelligence to accelerate research on brain function and NPDs. This resource will be made available for broad use by the biomedical community. Projects that propose to build on the DRACC's current role in refining methods and standards to harmonize data from the SSPsyGene Assay and Data Generation Centers and facilitate submission to data archives are encouraged. This is a forecast for a single s
Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional)
National Institutes of Health · Deadline 2027-06-02
The purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate precision probiotic interventions using a milestone-driven, biphasic award mechanism, R61/R33 Phased Innovation Award. Specifically, this NOFO solicits applications that will characterize person-specific features affecting probiotic responses to identify subgroups of probiotic responders and to enhance probiotic clinical outcomes. The ultimate goal of this NOFO is to identify, understand, and develop strategies to address barriers in precision probiotic therapies to account for the heterogenicity in humans that causes inconsistent probiotic responses. The first phase, funded by the R61, will providing for up to 2 years to identify unique host biological patterns (e.g., native microbiome, immune system, gender, diet, age, genetic background, lifestyle, and health history) that are correlated with heterogeneity of probiotic clinical effects using observational or secondary data analysis studies. The second phase, funded under the R33, will support studies to assess the ability of the unique patterns determined in the R61 phase to detect the improvement of probio
Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)
National Institutes of Health · Deadline 2027-06-02
The purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate precision probiotic interventions. Specifically, this NOFO solicits R33 applications that will characterize person-specific features affecting probiotic responses to identify subgroups of probiotic responders and to enhance probiotic clinical outcomes. The ultimate goal of this NOFO is to identify, understand, and develop strategies to address barriers in precision probiotic therapies to account for the heterogenicity in humans that causes inconsistent probiotic responses. This NOFO will support studies to assess the ability of the unique patterns of host biology (e.g., native microbiome, immune system, gender, diet, age, genetic background, lifestyle, and health history) that are correlated with probiotic usage to detect the improvement of probiotic responsiveness. Well-suited applications must offer rigorously designed mechanistic studies using relevant/innovative animal models or in human subjects. This NOFO is intended to support projects where potential host biological patterns that are correlated with probiotic usage have been identified, as demonstrated
Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
National Institutes of Health · Deadline not published
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies for cancer research or clinical care. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development, enhancements, optimizations, and rigorous technical validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, and/or epidemiology. Projects that are in-scope include technologies with new or significantly improved technical capabilities to measure, analyze, model, or interrogate cancer-related systems. These may include, but are not limited to, advanced molecular and cellular analysis platforms, multi-omic and spatial profiling methods, imaging and sensing technologies, immuno-engineering approaches, and innovations in bi Awards up to $300,000.